A Phase 2 interventional study of Cyclophosphamide and Fludarabine in Lymphocytic Leukemia, Chronic, sponsored by Hoffmann-La Roche. Completed at 12 sites in Israel. Open to participants aged 65 Years and older. Per ClinicalTrials.gov, last updated 2018-04-23.
Sponsored by Hoffmann-La Roche · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 155 studies testing cyclophosphamide in Leukemia, Lymphocytic, Chronic, B-Cell — 3 open to participants now, 11 under way, none of them phase 3. Cyclophosphamide · Leukemia, Lymphocytic, Chronic, B-Cell.
Among the 155 studies testing cyclophosphamide in Leukemia, Lymphocytic, Chronic, B-Cell, this one is the 79th largest by enrollment of the 145 interventional ones that give a count, is one of 8 that started in 2011, is one of 100 in phase 2, and was the 110th registered.
2,036 studies on the registry are indexed under Leukemia, Lymphocytic, Chronic, B-Cell; 236 are open to participants now.
Browse Leukemia, Lymphocytic, Chronic, B-Cell studies →3 of the 155 studies testing cyclophosphamide in Leukemia, Lymphocytic, Chronic, B-Cell are open now, in 1 country. Recruiting first, the newest first:
Mayo Clinic · Sites in United States
Ages 18+
Medical University of South Carolina · Sites in United States
Ages 18+
Masonic Cancer Center, University of Minnesota · Sites in United States
Ages up to 75
By country, each count listing its studies:
Cyclophosphamide: first FDA approval 1959 (CYTOXAN). What it is approved for, and how studies give it, is on its page →
Of the 187 Leukemia, Lymphocytic, Chronic, B-Cell studies recruiting now, 150 (80%) set no upper age limit and 15 (8%) stop at 75 or younger; 17 take children under 18; 12 take healthy volunteers.
This study: 65 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
155 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 35 · Phase 2 114 · Phase 3 11 · Phase 4 3
First in 1988; this study’s year is marked. 8 started in 2011.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 42 is close to the median of 39 across 1,603 interventional studies indexed under Leukemia, Lymphocytic, Chronic, B-Cell.
Median enrollment 49 across the 145 interventional studies. Of the 132 that completed or were terminated, 77 (58%) have results posted.
This tab as a report to print or save as PDF → With an account.
9 of 155 have an industry lead sponsor. The 10 most frequent:
Hoffmann-La Roche is the lead sponsor of 2,102 studies on the registry; 89 are open to participants now.
Of its 330 completed or terminated interventional studies of FDA-regulated products, 248 (75%) have results posted.
48 studies in Leukemia, Lymphocytic, Chronic, B-Cell by Hoffmann-La Roche: 1 open now, 2 under way, none of them phase 3. Of 46 finished, 28 (61%) have results posted.
Among the 48 studies in Leukemia, Lymphocytic, Chronic, B-Cell by Hoffmann-La Roche, this one is the 29th largest by enrollment of the 36 interventional ones that give a count, is one of 8 that started in 2011, is one of 13 in phase 2, and was the 16th registered.
Hoffmann-La Roche’s Leukemia, Lymphocytic, Chronic, B-Cell studies by the year they started, since 2003.
4 of the studies testing cyclophosphamide in Leukemia, Lymphocytic, Chronic, B-Cell that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT00466531Memorial Sloan Kettering Cancer CenterTreatment of Relapsed or Chemotherapy Refractory Chronic Lymphocytic Leukemia or Indolent B Cell Lymphoma Using Autologous T Cells Genetically Targeted to the B Cell Specific Antigen CD19 | 2026-12 |
| NCT06001385Center for International Blood and Marrow Transplant ResearchHLA-Mismatched Unrelated Donor Peripheral Blood Stem Cell Transplantation With Reduced Dose Post Transplantation Cyclophosphamide GvHD Prophylaxis | 2026-12-24 |
| NCT02153580City of Hope Medical CenterCellular Immunotherapy Following Chemotherapy in Treating Patients With Recurrent Non-Hodgkin Lymphomas, Chronic Lymphocytic Leukemia, or B-Cell Prolymphocytic Leukemia | 2027-08-11 |
| NCT05805605Masonic Cancer Center, University of MinnesotaAllo HSCT Using RIC and PTCy for Hematological Diseases | 2027-10-22 |
Add all 4 to your calendar (.ics) → With an account.
Among the 155 studies testing cyclophosphamide in Leukemia, Lymphocytic, Chronic, B-Cell, from their registry updates:
Among Hoffmann-La Roche’s 48 in Leukemia, Lymphocytic, Chronic, B-Cell:
This tab as a report to print or save as PDF → With an account.
This single arm, open-label study will assess the safety and efficacy of low dose fludarabine and cyclophosphamide in combination with standard dose MabThera/Rituxan (rituximab) as primary therapy in elderly patients (>/= 65 years) with chronic lymphocytic leukemia. Patients will receive six 28-day cycles of treatment with Mabthera/Rituxan (375 mg/m2 intravenously [iv] Day 0 of cycle 1, 500 mg/m2 iv Day 1 of cycles 2-6), fludarabine (12.5 mg/m2/d iv Days 1-3, cycles 1-6) and cyclophosphamide (150 mg/m2/d iv Days 1-3, cycles 1-6). Anticipated time on study treatment is 6 months, with a 30-month follow-up period.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Elderly participants with chronic lymphocytic leukemia (CLL) will receive combination treatment with low-dose fludarabine and cyclophosphamide combined with standard-dose of rituximab for 6 months. Treatment is followed by a follow up period of 36 months.
Drug: Cyclophosphamide · Drug: Fludarabine · Drug: Rituximab
150 milligrams per square meter (mg/m\^2) intravenously (IV) on Days 1-3 of each 28-day cycle for 6 cycles
12.5 mg/m\^2 IV on Days 1-3 of every 28-day cycle for 6 cycles
375 mg/m\^2 IV Day 0 of Cycle 1, 500 mg/m\^2 IV Day 1 of Cycles 2-6. Each cycle was 28 days.
Also known as: MabThera/Rituxan
Overall Response Rate
Overall response rate was defined as the percentage of participants with a complete response (CR) or a partial response (PR) according to National Cancer Institute - Working Group \[NCI-WG\] guidelines. CR: no clonal B lymphocytes in peripheral blood, no significant lymphadenopathy, liver and spleen normal size, no disease symptoms, blood counts: absolute neutrophil count (ANC) \>1,500/microliter (mcL), platelets \> 100,000/mcL, hemoglobin \> 11.0 grams/deciliter (g/dL), normocellular bone marrow. PR: \>/= 50% decrease in clonal B lymphocyte count, \>/= 50% reduction in lymphadenopathy, \>/= 50% reduction of liver or spleen enlargement and ANC \>1,500/mcL, platelets \> 100,000/mcL, hemoglobin \> 11.0 g/dL OR \>/= 50% increase in ANC, platelets or hemoglobin.
Time frame: Up to 42 months
Percentage of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs)
An AE is any untoward medical occurrence in a participant administered a pharmaceutical product and which does not necessarily have to have a causal relationship with the treatment. Preexisting conditions which worsen during a study are also considered as adverse events. An SAE is any experience that suggests a significant hazard, contraindication, side effect, or precaution, and fulfills any of the following criteria: fatal (resulted in death), life-threatening, required in-patient hospitalization or prolongation of existing hospitalization, resulted in persistent or significant disability/incapacity, was a congenital anomaly/birth defect, was medically significant or required intervention to prevent any of the other outcomes listed here.
Time frame: Up to 53 months
Percentage of Participants With Neutropenic Fever, Infection, >/= Grade 3 Drug-Related Neutropenia, >/= Grade 3 Drug-Related Thrombocytopenia, Hospitalizations
Time frame: Up to 53 months
Hospitalization Days
Time frame: Up to 53 months
Progression-free Survival (PFS)
PFS was defined as the interval from the first study drug treatment day to the first sign of disease progression according to NCI-WG guidelines. Progressive disease (PD): Any new lesion, any disease symptoms, \>/=50% increase in lymphadenopathy, splenomegaly, hepatomegaly, \>/= 50% increase in the number of circulating clonal B lymphocytes, decrease of hemoglobin levels by \> 2.0 g/dL, \>/= 50% decrease of platelet counts, increase of lymphocytes in bone marrow to more than 30% from normal.
Time frame: Up to 53 months
Quality of Life (QoL): Functional Assessment of Chronic Illness Therapy Fatigue (FACIT-F) Questionnaire
The FACIT-F questionnaire consists of 13 questions with a total score range of 0 to 52 with 0 indicating a better outcome and 52 indicating a worse outcome.
Time frame: [Visit 1 (Screening, Week 0), at Visits 11 (Week 45) and 14 (Week 80) and at the end of the study (Month 42)]
| Milestone | Rituximab Plus Fludarabine and Cyclophosphamide |
|---|---|
| Started | 42 |
| Completed | 13 |
| Not completed | 29 |
| Withdrew: Progressive disease | 18 |
| Withdrew: Adverse event | 3 |
| Withdrew: Death | 2 |
| Withdrew: Patient withdrew consent | 2 |
| Withdrew: Eligibility criteria not fulfilled | 1 |
| Withdrew: Lost to follow-up | 1 |
| Withdrew: Colon metastases | 1 |
| Withdrew: Principal investigator (pi) decision | 1 |
Overall response rate was defined as the percentage of participants with a complete response (CR) or a partial response (PR) according to National Cancer Institute - Working Group \[NCI-WG\] guidelines. CR: no clonal B lymphocytes in peripheral blood, no significant lymphadenopathy, liver and spleen normal size, no disease symptoms, blood counts: absolute neutrophil count (ANC) \>1,500/microliter (mcL), platelets \> 100,000/mcL, hemoglobin \> 11.0 grams/deciliter (g/dL), normocellular bone marrow. PR: \>/= 50% decrease in clonal B lymphocyte count, \>/= 50% reduction in lymphadenopathy, \>/= 50% reduction of liver or spleen enlargement and ANC \>1,500/mcL, platelets \> 100,000/mcL, hemoglobin \> 11.0 g/dL OR \>/= 50% increase in ANC, platelets or hemoglobin.
| percentage of participants | Rituximab Plus Fludarabine and Cyclophosphamide |
|---|---|
| Overall Response Rate | 67.5 (50.9 to 81.4) |
An AE is any untoward medical occurrence in a participant administered a pharmaceutical product and which does not necessarily have to have a causal relationship with the treatment. Preexisting conditions which worsen during a study are also considered as adverse events. An SAE is any experience that suggests a significant hazard, contraindication, side effect, or precaution, and fulfills any of the following criteria: fatal (resulted in death), life-threatening, required in-patient hospitalization or prolongation of existing hospitalization, resulted in persistent or significant disability/incapacity, was a congenital anomaly/birth defect, was medically significant or required intervention to prevent any of the other outcomes listed here.
| percentage of participants | Rituximab Plus Fludarabine and Cyclophosphamide |
|---|---|
| AEs | 97.6 |
| SAEs | 45.2 |
| percentage of participants | Rituximab Plus Fludarabine and Cyclophosphamide |
|---|---|
| Infection | 47.6 |
| Neutropenic fever | 14.3 |
| ≥ Grade 3 drug-related neutropenia | 47.6 |
| ≥ Grade 3 drug-related thrombocytopenia | 11.9 |
| Hospitalization | 19.1 |
| days | Rituximab Plus Fludarabine and Cyclophosphamide |
|---|---|
| Hospitalization Days | 8 (2 to 13) |
PFS was defined as the interval from the first study drug treatment day to the first sign of disease progression according to NCI-WG guidelines. Progressive disease (PD): Any new lesion, any disease symptoms, \>/=50% increase in lymphadenopathy, splenomegaly, hepatomegaly, \>/= 50% increase in the number of circulating clonal B lymphocytes, decrease of hemoglobin levels by \> 2.0 g/dL, \>/= 50% decrease of platelet counts, increase of lymphocytes in bone marrow to more than 30% from normal.
| months | Rituximab Plus Fludarabine and Cyclophosphamide |
|---|---|
| Progression-free Survival (PFS) | 36.1 (27.3 to 48.1) |
The FACIT-F questionnaire consists of 13 questions with a total score range of 0 to 52 with 0 indicating a better outcome and 52 indicating a worse outcome.
| score on a scale | Rituximab Plus Fludarabine and Cyclophosphamide |
|---|---|
| Visit 1 (Screening, Week 0) | 36.1 ± 11.1 |
| Visit 11 (Week 45) | 39.4 ± 9.2 |
| Visit 14 (Week 80) | 40.2 ± 10.1 |
| End of the Study (Month 42) | 47.0 ± 1.0 |
Collected over Up to 53 months. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Rituximab Plus Fludarabine and Cyclophosphamide | 2/42 (4.8%) | 19/42 (45.2%) | 41/42 (97.6%) |
| Event | Rituximab Plus Fludarabine and Cyclophosphamide |
|---|---|
| Febrile neutropeniaBlood and lymphatic system disorders | 6/42 |
| PyrexiaGeneral disorders | 3/42 |
| PneumoniaInfections and infestations | 3/42 |
| LeukopeniaBlood and lymphatic system disorders | 1/42 |
| ThrombocytopeniaBlood and lymphatic system disorders | 1/42 |
| Diabetes mellitusEndocrine disorders | 1/42 |
| Pancreatitis acuteGastrointestinal disorders | 1/42 |
| ChillsGeneral disorders | 1/42 |
| Herpes zosterInfections and infestations | 1/42 |
| Pneumonia bacterialInfections and infestations | 1/42 |
| Event | Rituximab Plus Fludarabine and Cyclophosphamide |
|---|---|
| NeutropeniaBlood and lymphatic system disorders | 22/42 |
| AnemiaBlood and lymphatic system disorders | 14/42 |
| ThrombocytopeniaBlood and lymphatic system disorders | 10/42 |
| CoughRespiratory, thoracic and mediastinal disorders | 10/42 |
| AstheniaGeneral disorders | 8/42 |
| ConstipationGastrointestinal disorders | 7/42 |
| DiarrheaGastrointestinal disorders | 7/42 |
| NauseaGastrointestinal disorders | 7/42 |
| RashSkin and subcutaneous tissue disorders | 6/42 |
| Infusion related reactionGeneral disorders | 5/42 |
Intent-to-Treat (ITT) population included all enrolled participants.
| Age, Continuous(years) | Rituximab Plus Fludarabine and Cyclophosphamide |
|---|---|
| Mean | 72.9 ± 5.0 |
| Sex: Female, Male(Participants) | Rituximab Plus Fludarabine and Cyclophosphamide |
|---|---|
| Female | 13 |
| Male | 29 |
| Race and Ethnicity Not Collected(Participants) | Rituximab Plus Fludarabine and Cyclophosphamide |
|---|
PDFs hosted by the registry, ClinicalTrials.gov.
Ran from Jul 2011 to primary completion in Apr 2017, 68 months.
Results were first posted in Apr 2018, 1 year after primary completion.
Of 41 industry-sponsored phase 2 interventional studies under Leukemia, Lymphocytic, Chronic, B-Cell, half reached primary completion within 55 months of starting (the median), counting those still running; a quarter within 26 and three quarters within 87. This study's 68 months is above that.
Counting every sponsor, half of 249 studies reached it within 73 months; a quarter within 41 and three quarters within 114.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Apr 2018. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Cyclophosphamide · Fludarabine · Rituximab
Leukemia, Lymphocytic, Chronic, B-Cell →